BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors reduce major
cardiovascular events, but are not tolerated by about 20% of patients. We therefore …

BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors reduce mortality,
myocardial infarction, stroke, heart failure, need for revascularization, nephropathy, and …

Background In patients who have vascular disease or high-risk diabetes without heart
failure, angiotensin-converting–enzyme (ACE) inhibitors reduce mortality and morbidity from …

The Heart Outcomes Prevention Evaluation (HOPE) study conclusively demonstrated that
ramipril, an angiotensin-converting enzyme (ACE) inhibitor, reduces the risk of …

Background—Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor
blockers reduce left ventricular hypertrophy (LVH). The effect of these drugs on LVH in high …

Objectives: The aim of this study was to determine whether telmisartan decreases all-cause
and cardiovascular mortality and morbidity in hemodialysis patients with chronic heart failure …

Background Angiotensin-converting-enzyme (ACE) inhibitors improve outcome of patients
with chronic heart failure (CHF). A substantial proportion of patients, however, experience no …

Objective: To determine whether age, gender, concomitant disease and/or previous or
present antihypertensive medication affect the safety or antihypertensive efficacy of …

Proven cardiovascular benefit from angiotensin-converting enzyme (ACE) inhibition is a
cornerstone of evidence-based medicine. The first study to show dramatic benefits from ACE …

Objectives To compare the efficacy and safety of angiotensin-converting enzyme inhibitors
(ACEis) and angiotensin receptor blockers (ARBs) in patients without heart failure. Patients …